This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
by Zacks Equity Research
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.
Compared to Estimates, Baxter (BAX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 3.03% and 1.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
by Zacks Equity Research
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 55.56% and 14.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.
Perrigo (PRGO) Q2 Earnings Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 10.42% and 5.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Baxter (BAX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Baxter (BAX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
by Zacks Equity Research
Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.
Should Value Investors Buy Baxter International (BAX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit
by Zacks Equity Research
Carlyle Group (CG) is in talks to acquire Baxter's kidney care unit. The companies started exclusive negotiations in late June and an agreement could be announced as soon as this week.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Company News for July 8, 2024
by Zacks Equity Research
Companies In The News Article are: M, LI, BAX, CG and AMD.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Baxter International (BAX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.